ATE246513T1 - Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten - Google Patents

Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten

Info

Publication number
ATE246513T1
ATE246513T1 AT94918667T AT94918667T ATE246513T1 AT E246513 T1 ATE246513 T1 AT E246513T1 AT 94918667 T AT94918667 T AT 94918667T AT 94918667 T AT94918667 T AT 94918667T AT E246513 T1 ATE246513 T1 AT E246513T1
Authority
AT
Austria
Prior art keywords
growth factor
cancer
present
antibodies specific
immunogenic
Prior art date
Application number
AT94918667T
Other languages
English (en)
Inventor
Carol A Nacy
John W Holaday
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc filed Critical Entremed Inc
Application granted granted Critical
Publication of ATE246513T1 publication Critical patent/ATE246513T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94918667T 1993-05-27 1994-05-26 Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten ATE246513T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6871793A 1993-05-27 1993-05-27
PCT/US1994/005927 WO1994027635A1 (en) 1993-05-27 1994-05-26 Compositions and methods for treating cancer and hyperproliferative disorders

Publications (1)

Publication Number Publication Date
ATE246513T1 true ATE246513T1 (de) 2003-08-15

Family

ID=22084279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94918667T ATE246513T1 (de) 1993-05-27 1994-05-26 Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten

Country Status (10)

Country Link
US (1) US5919459A (de)
EP (1) EP0702563B1 (de)
JP (2) JPH08510751A (de)
AT (1) ATE246513T1 (de)
AU (1) AU6989094A (de)
CA (1) CA2163652A1 (de)
DE (1) DE69433013T2 (de)
DK (1) DK0702563T3 (de)
ES (1) ES2204919T3 (de)
WO (1) WO1994027635A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248799A1 (en) * 1993-05-27 2004-12-09 Holaday John W. Compositions and methods for treating cancer and hyperproliferative disorders
US6805865B1 (en) * 1993-05-27 2004-10-19 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US6908910B2 (en) * 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
NZ512287A (en) 1998-12-11 2002-12-20 Pharmasolutions Inc Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
WO2000053219A2 (en) * 1999-03-11 2000-09-14 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US20060009393A1 (en) * 1999-10-02 2006-01-12 The Government of the U.S.A as represented by the Secretary of the Dept. of Health & Human Services Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)
US20020012651A1 (en) * 2000-05-10 2002-01-31 Loeb Marvin P. Release of therapeutic agents in a vessel or tissue
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
AU2002320079A1 (en) * 2001-06-11 2002-12-23 Jeong-Im Sin Vaccines, immunotherapeutics and methods of using the same
WO2003009868A1 (en) * 2001-07-26 2003-02-06 Otago Innovation Limited Antigenic compositions
AU2003247754A1 (en) * 2002-06-26 2004-01-19 Entremed, Inc Compositions and methods comprising protein activated receptor antagonists
EP1587484A4 (de) * 2002-12-19 2008-11-12 Alza Corp Verfahren zur behandlung von angiogenemgewebswachstum
AU2004275693A1 (en) * 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
DE10333509B4 (de) * 2003-07-18 2007-05-03 Technische Universität Dresden Gegen VEGF gerichtete Erkennungsmoleküle und die Verwendung dieser
EP1756139A4 (de) 2004-03-12 2009-07-29 Entremed Inc Antiangiogene mittel
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
EP1819343A2 (de) * 2004-11-29 2007-08-22 EntreMed, Inc. Verfahren zur verabreichung von antiangiogenen mitteln und verfahren zur behandlung von krankheiten damit
AU2006235507B2 (en) * 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
US8399440B2 (en) * 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
WO2008109119A2 (en) * 2007-03-05 2008-09-12 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods of use thereof
AU2008239628B2 (en) * 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2413951A4 (de) 2009-04-03 2015-05-20 Univ Duke Formulierung zur herbeiführung einer breit reaktiven neutralisierung von hiv-antikörpern
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2011140296A1 (en) * 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
JP6956950B2 (ja) * 2016-12-27 2021-11-02 国立研究開発法人国立循環器病研究センター リポソーム組成物及び炎症性疾患用治療剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4879236A (en) * 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5194384A (en) * 1987-04-23 1993-03-16 Bystryn Jean Claude Method for preparing human meloma vaccine
US4895835A (en) * 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
WO1993025225A1 (en) * 1992-06-17 1993-12-23 University Of Massachusetts Medical Center Liposomal formulations for administering to cancer patients
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein

Also Published As

Publication number Publication date
CA2163652A1 (en) 1994-12-08
DE69433013T2 (de) 2004-06-03
AU6989094A (en) 1994-12-20
JPH08510751A (ja) 1996-11-12
DK0702563T3 (da) 2003-11-10
DE69433013D1 (de) 2003-09-11
EP0702563A4 (de) 1997-10-01
EP0702563A1 (de) 1996-03-27
JP2007262102A (ja) 2007-10-11
EP0702563B1 (de) 2003-08-06
ES2204919T3 (es) 2004-05-01
WO1994027635A1 (en) 1994-12-08
US5919459A (en) 1999-07-06

Similar Documents

Publication Publication Date Title
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
DE69032484D1 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
BR9510575A (pt) Anticorpos monoclonais contra hiv-1 vacinas preparadas com eles
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
ATE193827T1 (de) Verwendung von 1-2-4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
ATE386808T1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
DE69433590D1 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
GEP20002145B (en) Stem Cell Factor
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE69213943T2 (de) Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern
AU4258101A (en) Combination therapies with vascular damaging activity
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ATE287958T1 (de) Verbesserte krebstherapie
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
AT409086B (de) Neue verwendung von antikörpern als impfstoffe
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
JPH05508769A (ja) 細胞培養及び治療に有用なβ―アレチン
WO2003097092A1 (de) Verwendung eines impfstoffes zur aktiven immunisierung gegen krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0702563

Country of ref document: EP

REN Ceased due to non-payment of the annual fee